Clinical Trials Browser

Phase 1/2 × epratuzumab × Clear all

NCT00421395 2021-08-16

Safety Study of NHL With 90Y-hLL2 IgG

Phase 1/2 Completed

Lymphoma, Non-Hodgkin

NCT01279707 2014-07-14

MARALL

Phase 1/2 Unknown

Burkitt Lymphoma, Recurrence